Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Eisai Creates US Subsidiary H3 Biomedicine with up to $200M

Eisai Creates US Subsidiary H3 Biomedicine with up to $200M

Jan 28, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Japanese drug firm Eisai has launched US subsidiary H3 Biomedicine with up to $200 million in funding to develop new oncology drugs based on patient genetic information.

Based in Cambridge, Mass., H3 Biomedicine aims to take a personalized medicine approach to developing such drugs by leveraging new insights into the genetic basis of cancer and advances in modern chemistry.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Free of Influence

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

Avoiding the MARCH1 to 1-Mar Change

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

Nature Papers Reveal Tuatara Genome, Cell Populations Involved in Lupus

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

Overlooked Expertise

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep
02
Featured Webinar

Spatial Profiling to Assess a Novel Gene Therapy in a Mouse Model of a Rare Genetic Disorder

Sponsored by
ACD

This webinar will discuss the use of digital spatial profiling to test a gene therapy for CDKL5 deficiency disorder (CDD), a rare X-linked neurodevelopmental disease that causes severe seizures, global developmental delay, and limits a patient’s ability to communicate.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.